From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
METTL3 activator-1 (2-Piperazinecarboxylic acid methyl ester dihydrochloride) is a Mettl3 activator that can promote the expression of Mettl3. METTL3 activator-1 can be used for the study of liver fibrosis .
METTL3-IN-8 (F039-0002) is a potent METTL3 inhibitor. METTL3-IN-8 strongly ameliorates Dextran sulfate sodium salt (DSS) (HY-116282C)-induced colitis. METTL3-IN-8 can be used Inflammatory bowel disease (IBD) research .
METTL3 Human Pre-designed siRNA Set A contains three designed siRNAs for METTL3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Mettl3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mettl3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Mettl3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Mettl3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
METTL3-IN-5 (Compound 13) is a METTL3 inhibitor. METTL3-IN-5 inhibits MOLM-13 growth with an IC50 less than 2 μM. METTL3-IN-5 has weak hERG inhibitory activity (IC50 >30 μM). METTL3-IN-5 can be used for AML research .
METTL3-IN-7 (7460-0250) is a potent METTL3 inhibitor. METTL3-IN-7 strongly ameliorates Dextran sulfate sodium salt (DSS) (HY-116282C)-induced colitis. METTL3-IN-7 can be used Inflammatory bowel disease (IBD) research .
METTL3-IN-9 (compound C3) is an inhibitor of methyltransferase-like METTL3, an RNA methyltransferase that catalyzes the N6-methyladenosine (m6A) modification of mRNA in eukaryotic cells .
PROTAC METTL3-14 degrader 1 (compound 30) is a PROTAC degrader of METTL3-14. PROTAC METTL3-14 degrader 1 shows a 50% or higher degradation of METTL3 and/or METTL14(Pink: Ligand for target protein (HY-115717); Black: Linker (HY-168686); Blue: Ligand for E3 ligase (HY-10984)) .
UZH1a is a potent and selective METTL3 inhibitor, with an IC50 of 280 nM. UZH1a can be used for epitranscriptomic modulation of cellular processes. UZH1a has antitumor activity. UZH1a also can be used as a chemical probe for studying METTL3 .
AF151 is a METTL3 PROTAC degrader with the DC50 of 0.43 μM in MOLM-13 cells. AF151 inhibits cell growth by significantly degrading METTL3 protein and reducing m6A levels. AF151 can induce cell apoptosis and reduce the level of Bcl-2 protein. AF151 can be used for research on cancer such as acute myeloid leukemia (AML). (Pink: METTL3 Ligand (HY-174874); Blue: VHL Ligand (HY-125845); Black: Linker; VHL Ligand+Linker (HY-174875)) .
UZH1 is a racemate of UZH1a and UZH1b. UZH1a is a potent and selective METTL3 inhibitor, with an IC50 of 280 nM. UZH1b (IC50=28 µM) is essentially inactive. UZH1 can be used for epitranscriptomic modulation of cellular processes. UZH1 has antitumor activity. UZH1 also can be used as a chemical probe for studying METTL3 .
SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 µM .
SAH-d4 is the deuterium labeled SAH. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 μM .
SAH- 13C10 is the 13C labeled SAH . SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 μM [3].
SAH (Standard) is the analytical standard of SAH. This product is intended for research and analytical applications. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 μM .
WD6305 is a potent and selective METTL3-METTL14 PROTAC degrader. WD6305 has DC50 values of 140 nM and 194 nM for METTL3 and METTL14, respectively. WD6305 inhibits m 6A modification and proliferation of AML cells, and induces apoptosis. WD6305 has antitumor activity .(Pink: UZH2 (HY-115717); Black: Linker; Blue: VHL ligand (HY-150803))
WD6305 TFA is a potent and selective METTL3-METTL14 PROTAC degrader. WD6305 TFA has DC50 values of 140 nM and 194 nM for METTL3 and METTL14, respectively. WD6305 TFA inhibits m 6A modification and proliferation of AML cells, and induces apoptosis. WD6305 TFA has antitumor activity .(Pink: UZH2 (HY-115717); Black: Linker; Blue: VHL ligand (HY-150803))
RSM3, a stapled peptide, is a METTL3-METTL14 inhibitor with an Kd of 3.10 μM. RSM3 inhibits tumor growth while induces cell apoptosis. RSM3 can be used for study of cancer .
RSM3 TFA, a stapled peptide, is a METTL3-METTL14 inhibitor with an Kd of 3.10 μM. RSM3 TFA inhibits tumor growth while induces cell apoptosis. RSM3 TFA can be used for study of cancer .
Antiviral agent 23 (compound 11b) is an antiviral agent to enterovirus 71 (EV71) with an EC50 value of 94 nM. Antiviral agent 23 effectively suppresses the activity of METTL3/METTL14. Antiviral agent 23 can be used for the research of infection .
STM2457 is a first-in-class, highly potent, selective and orally active METTL3 inhibitor with an IC50 of 16.9 nM. STM2457 can be used for the research of acute myeloid leukaemia (AML) .
Antiviral agent 24 is a potent antiviral agent with EC50 values of 0.101, 19.9, 91.2 µM for EV71, CVA21, EV68, respectively. Antiviral agent 24 inhibits METTL3/METTL14 activity in a dose-dependent manner .
E3 Ligase Ligand-linker Conjugate 137 is the linker and E3 ligase ligand for the PROTACMETTL3-14 degrader 1 (HY-162282), which can be used for research on acute myeloid leukemia .
EP652 (compound 56) potently inhibits the enzymatic activity of METTL3, with the IC50s of 2 nM, ＜ 10 nM anf 37 nM in SPA, intracellular and ATPlite assay, respectively. EP652 plays an important role in liquid and solid tumors research .
STM3006 is a highly potent, selective, and orally active inhibitor of METTL3 (IC50: 5 nM). STM3006 can reduce the m6A level, promote the formation of dsRNA, trigger a cell-intrinsic interferon response, and enhance the killing effect of T cells on tumors. STM3006 has anti-tumor activity, and its combination with anti-PD-1 immunotherapy yields better results .
STC-15 is an orally active RNA methyltransferase METTL3 inhibitor with the activity of activating anti-tumor immunity and reshaping the tumor microenvironment. STC-15 inhibits tumor growth by activating anti-cancer immune responses associated with increased interferon signaling and synergizes with T-cell checkpoint blockade. STC-15 can be used in the study of proliferative diseases such as cancer and autoimmune diseases [3].
METTL1-WDR4-IN-2, an adenosine derivative, is a selective methyltransferase Like 1 (METTL1)-WDR4 inhibitor with an IC50 of 41 μM. METTL1-WDR4-IN-2 shows selectivity against METTL3-14 (IC50 of 958 μM) and METTL16 (IC50 of 208 μM). METTL1-WDR4-IN-2 can be used for the study of cancer .
N6-Methyladenosine (Standard) is the analytical standard of N6-Methyladenosine. This product is intended for research and analytical applications. N6-Methyladenosine is the most prevalent internal (non-cap) modification present in the messenger RNA (mRNA) of all higher eukaryotes. N6-Methyladenosine can modifies viral RNAs and has antiviral activities.
In Vitro: N6-methyladenosine (m6A) is selectively recognized by the human YTH domain family 2 (YTHDF2) protein to regulate mRNA degradation. N6-methyladenosine (m6A), a prevalent internal modification in the messenger RNA of all eukaryotes, is post-transcriptionally installed by m6A methyltransferase (e.g., MT-A70) within the consensus sequence of G(m6A)C (70%) or A(m6A)C (30%). N6-methyladenosine (m6A)-containing RNAs are greatly enriched in the YTHDF-bound portion and diminished in the flow-through portion . N6-methyladenosine (m6A), the most abundant internal RNA modification, functions in diverse biological processes, including regulation of embryonic stem cell self-renewal and differentiation. N6-methyladenosine (m6A) is a large protein complex, consisting in part of methyltransferase-like 3 (METTL3) and methyltransferase-like 14 (METTL14) catalytic subunits .
RSM3, a stapled peptide, is a METTL3-METTL14 inhibitor with an Kd of 3.10 μM. RSM3 inhibits tumor growth while induces cell apoptosis. RSM3 can be used for study of cancer .
RSM3 TFA, a stapled peptide, is a METTL3-METTL14 inhibitor with an Kd of 3.10 μM. RSM3 TFA inhibits tumor growth while induces cell apoptosis. RSM3 TFA can be used for study of cancer .
SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 µM .
SAH (Standard) is the analytical standard of SAH. This product is intended for research and analytical applications. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 μM .
N6-Methyladenosine (Standard) is the analytical standard of N6-Methyladenosine. This product is intended for research and analytical applications. N6-Methyladenosine is the most prevalent internal (non-cap) modification present in the messenger RNA (mRNA) of all higher eukaryotes. N6-Methyladenosine can modifies viral RNAs and has antiviral activities.
In Vitro: N6-methyladenosine (m6A) is selectively recognized by the human YTH domain family 2 (YTHDF2) protein to regulate mRNA degradation. N6-methyladenosine (m6A), a prevalent internal modification in the messenger RNA of all eukaryotes, is post-transcriptionally installed by m6A methyltransferase (e.g., MT-A70) within the consensus sequence of G(m6A)C (70%) or A(m6A)C (30%). N6-methyladenosine (m6A)-containing RNAs are greatly enriched in the YTHDF-bound portion and diminished in the flow-through portion . N6-methyladenosine (m6A), the most abundant internal RNA modification, functions in diverse biological processes, including regulation of embryonic stem cell self-renewal and differentiation. N6-methyladenosine (m6A) is a large protein complex, consisting in part of methyltransferase-like 3 (METTL3) and methyltransferase-like 14 (METTL14) catalytic subunits .
SAH-d4 is the deuterium labeled SAH. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 μM .
SAH- 13C10 is the 13C labeled SAH . SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 μM [3].
METTL3 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 64 kDa, targeting to METTL3. It can be used for WB,IHC-P,FC assays with tag free, in the background of Human, Mouse, Rat.
N6-adenosine-methyltransferase 70 kDa subunit; MT-A70; Methyltransferase-like protein 3;
WB, IHC-P, ICC/IF, IP, ELISA
Human, Mouse, Rat
METTL3 Antibody (YA6290) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to METTL3. It can be applicated for WB, IHC-P, ICC/IF, IP, ELISA assays, in the background of human, mouse, rat.
SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 µM .
METTL3 Human Pre-designed siRNA Set A contains three designed siRNAs for METTL3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Mettl3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mettl3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Mettl3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Mettl3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Inquiry Online
Your information is safe with us. * Required Fields.
